Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
3.340
+0.210 (6.71%)
At close: Mar 6, 2026, 4:00 PM EST
3.301
-0.039 (-1.18%)
After-hours: Mar 6, 2026, 7:38 PM EST
Fortress Biotech Employees
Fortress Biotech had 101 employees as of December 31, 2024. The number of employees decreased by 85 or -45.70% compared to the previous year.
Employees
101
Change (1Y)
-85
Growth (1Y)
-45.70%
Revenue / Employee
$616,861
Profits / Employee
-$52,832
Market Cap
103.67M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Codexis | 188 |
| aTyr Pharma | 65 |
| Biomea Fusion | 42 |
| Vivani Medical | 37 |
| Gain Therapeutics | 25 |
| iBio, Inc. | 20 |
| TuHURA Biosciences | 19 |
| Dogwood Therapeutics | 12 |
FBIO News
- 12 days ago - UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - GlobeNewsWire
- 12 days ago - Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - GlobeNewsWire
- 12 days ago - Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease - GlobeNewsWire
- 15 days ago - Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap - Seeking Alpha
- 7 weeks ago - Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States - GlobeNewsWire
- 2 months ago - Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission - GlobeNewsWire
- 3 months ago - Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology - GlobeNewsWire
- 4 months ago - Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire